Baxter International, Inc. · Polyclonal Antibodies · Polyclonal Antibodies
immune globulin intravenous is a polyclonal antibodies developed by Baxter International, Inc.. It is approved for therapeutic indications via injectable (others) or intravenous (iv).
| Brand Names | Iveegam, Immuno, Iveegam EN |
| Company | Baxter International, Inc. |
| Drug Class | Polyclonal Antibodies, Antibody |
| Route | Injectable (Others), Intravenous (IV) |
| Status | Approved |
immune globulin intravenous is developed for 5 unique indications across 3 therapeutic areas.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Immune system disorders | Selective IgG subclass deficiency | ✓ Approved |
| Infections and infestations | Borna virus infection | ✓ Approved |
| Musculoskeletal and connective tissue disorders | Dermatomyositis | Preclinical |
| Musculoskeletal and connective tissue disorders | Polymyositis | Preclinical |
| Musculoskeletal and connective tissue disorders | Juvenile idiopathic arthritis | Preclinical |
Wei Xiaowen X, Qin Tianyi T, Xu Zhongyong Z, Liu Bin B
A three-channel fluorescent sensor array based on GC-globulin (GCG) has been developed for the discrimination of androgens and estrogens.
Li Zhiqiang Z, Li Yufei Y, Zhang Yuhan Y, Ye Qiuxia Q et al.
Immune checkpoint inhibitors (ICIs), including novel bispecific antibodies targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have expanded therapeutic options but have also increased the incidence and complexity of immune-related adverse events (irAEs). Low-dose interleukin-2 (Ld-IL2) has been explored as a potential immunomodulatory strategy. However, its role in real-world combination regimens for managing severe cutaneous irAEs remains to be fully elucidated. We report the case of a patient with gastric cancer who developed rapidly progressive erythema and pruritus after treatment with iparomlimab and tuvonralimab. Symptoms worsened despite corticosteroids, intravenous immunoglobulin (IVIG) and antihistamines. After Ld-IL2 and thalidomide were added while corticosteroid treatment was continued, clinical improvement was observed within 48 hours, with complete resolution of the skin lesions at 2 weeks. Because Ld-IL2, thalidomide, and corticosteroids were administered concurrently, the independent contribution of each treatment and the underlying immunological mechanism could not be determined. However, further studies are warranted to clarify the potential value of this combined regimen in the management of such adverse events.
Zheng Zhiming Z, Li Jianrong J, Huang Qiang Q
This case report describes a 51-year-old woman with recurrent cervical squamous cell carcinoma who developed acute anaphylactic shock within 5-10 min of initiating intravenous cadonilimab infusion. The physician's order was placed at 16:04; however, the actual bedside infusion was initiated at approximately 20:00 without routine premedication. Five minutes after infusion start, she presented with pruritus and multiple erythematous maculopapular rashes over the trunk, followed by dyspnea, generalized flushing, profound hypotension (68/40 mmHg), oxygen desaturation (SpO2 82%), and altered consciousness. The infusion was immediately discontinued. Emergency treatment included subcutaneous epinephrine 0.5 mg, intramuscular diphenhydramine 20 mg, intravenous dexamethasone 10 mg, aggressive fluid resuscitation, and supplemental oxygen. Because refractory hypotension persisted, intravenous norepinephrine (4 mg via continuous pump) was initiated and maintained for approximately 72 h. Hemodynamic stability was restored within 45 min. Comprehensive evaluation excluded infection, cardiogenic shock, pulmonary embolism, and cytokine release syndrome. The event fulfilled World Allergy Organization diagnostic criteria for anaphylaxis and was graded as Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade 4. Causality assessment using the Naranjo scale yielded a score of 6, indicating a probable adverse drug reaction. The patient had a documented prior hypersensitivity to paclitaxel but no prior exposure to immune checkpoint inhibitors. Rechallenge was not attempted. Cadonilimab may rarely cause rapid-onset, life-threatening anaphylactic shock during the first infusion. Careful monitoring, immediate access to emergency management-including vasopressor support-and heightened awareness of bispecific antibody-associated hypersensitivity are essential.
Kurihara Shingo S, Ichita Chikamasa C, Goto Tadahiro T, Hatayama Kazuhisa K et al.
Although major international guidelines recommend discontinuing antibiotic prophylaxis within 24 hours after total joint arthroplasty, recent studies have suggested potential benefits of extended administration. The aim of this study was to evaluate the effectiveness of extended intravenous antibiotic prophylaxis in preventing periprosthetic joint infection (PJI). The Japanese Diagnosis Procedure Combination database was used to identify adults who underwent primary total knee arthroplasty (TKA) and total hip arthroplasty (THA) from April 2014 to March 2024. Based on the duration of postoperative intravenous antibiotic prophylaxis, patients were divided into the standard intravenous antibiotic prophylaxis (0-1 day) and extended intravenous antibiotic prophylaxis (2-3 days) groups. Patients who received any oral antibiotic prophylaxis during the intravenous prophylactic period were excluded. The outcome was PJI within 90 and 365 days after surgery, defined as surgical site infection requiring surgical intervention. Propensity score matching and subgroup analyses in high-risk patients were conducted (e.g., obesity, smoking, diabetes mellitus with chronic complications, kidney disease, hepatic disease, autoimmune disease, and oral corticosteroid use). Among 506,710 eligible patients (244,156 TKA and 262,554 THA), the 90-day PJI incidence was 0.34% in TKA and 0.37% in THA. In propensity score-matched analysis, extended intravenous antibiotic prophylaxis was associated with a small reduction in 90-day PJI after TKA, with a risk difference (RD) of -0.07% (95% confidence interval [CI], -0.12% to -0.01%) and a corresponding risk ratio (RR) of 0.83 (95% CI, 0.72-0.96). In high-risk TKA patients, a stronger association was observed (RD, -0.13% [95% CI, -0.25% to -0.01%]; RR, 0.78 [95% CI, 0.63-0.98]). Similar findings were observed for 365-day PJI after TKA. No clear association was observed in THA, either in the overall cohort or in the high-risk subgroup. Extended intravenous antibiotic prophylaxis was associated with a marginal reduction in PJI within 90 and 365 days after TKA, with a greater effect in high-risk TKA patients. While routine extension is not supported for all patients, it may be considered in selected high-risk TKA cases. Therapeutic Level Ⅲ. See Instructions for Authors for a complete description of levels of evidence.
Neuen Brendon L BL, Levin Adeera A
AbstractIron deficiency is common in patients with chronic kidney disease (CKD). Contemporary guidelines recommend the use of iron therapy only in the presence of anemia. However, patients with CKD are at increased risk of heart failure, and the coexistence of both conditions is associated with impaired quality of life, reduced physical function, and increased mortality compared with either condition alone. In this Tomorrow's Trial article, we review current evidence for intravenous iron in CKD and heart failure and propose the design of a randomized trial of intravenous iron, independent of hemoglobin, to assess its effects on mortality, heart failure, and physical function.
Short-Burchell Robert R, Druda Dino D, Hodgson Sarah S
+9996 more articles available with a free account
Sign up free to view all articles →